B, C and D at around δ 1.4 ppm, at around δ 2.5 ppm, at around δ 3.5 ppm and at around δ 9.8 ppm, respectively. The ratio of integrated intensity of these signals, A:B:C:D, is about 3:6:3:1.

Purity Heavy metals—Proceed with 2.0 g of Rokitamycin according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

Water Not more than 3.0% (0.2 g, volumetric titration, direct titration).

Residue on ignition Not more than 0.2% (1 g).

Assay Perform the test according to the Cylinder-plate method as directed under the Microbial Assay for Antibiotics according to the following conditions.

(1) Test organism—*Micrococcus luteus* ATCC 9341

(2) Culture medium—Use the medium i in 3) Medium for other organisms under (1) Agar media for seed and base layer. Adjust the pH of the medium so that it will be 7.8 to 8.0 after sterilization.

(3) Standard solution—Weigh accurately an amount of Rokitamycin Reference Standard equivalent to about 0.04 g (potency), dissolve in 50 mL of methanol, add 0.1 mol/L phosphate buffer solution, pH 4.5 to make exactly 100 mL, and use this solution as the standard stock solution. Keep the standard stock solution at 5°C or below and use within 10 days. Take exactly a suitable amount of the standard stock solution before use, add 0.1 mol/L phosphate buffer solution, pH 8.0 containing 0.01% of polysorbate 80 to make solutions so that each mL contains 2 μg (potency) and 0.5 μg (potency), and use these solutions as the high concentration standard solution and the low concentration standard solution, respectively.

(4) Sample solution—Weigh accurately an amount of Rokitamycin equivalent to about 0.04 g (potency), dissolve in 50 mL of methanol, and add 0.1 mol/L phosphate buffer solution, pH 4.5 to make exactly 100 mL. Take exactly a suitable amount of the solution, add 0.1 mol/L phosphate buffer solution, pH 8.0 containing 0.01% of polysorbate 80 to make solutions so that each mL contains 2 μg (potency) and 0.5 μg (potency), and use these solutions as the high concentration sample solution and the low concentration sample solution, respectively.

Containers and storage Containers—Tight containers.

Roxithromycin

ロキシスロマイシン



$C_{41}H_{76}N_2O_{15}$: 837.05

(2*R*,3*S*,4*S*,5*R*,6*R*,8*R*,10*R*,11*R*,12*S*,13*R*)-5-(3,4,6-Trideoxy-3-dimethylamino-β-D-*xylo*-hexopyranosyloxy)-3-(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl-α-L-*ribo*-hexopyranosyloxy)-6,11,12-trihydroxy-9-(2-methoxyethoxy)methoxyimino-2,4,6,8,10,12-hexamethylpentadecan-13-olide [*80214-83-1*]

Roxithromycin contains not less than 970 μg (potency) per mg, calculated on the anhydrous basis. The potency of Roxithromycin is expressed as mass (potency) of roxithromycin ($C_{41}H_{76}N_2O_{15}$).

Description Roxithromycin occurs as a white crystalline powder.

It is freely soluble in acetone and in ethanol (95), and practically insoluble in water.

Identification Determine the infrared absorption spectrum of Roxithromycin as directed in the potassium bromide disk method under the Infrared Spectrophotometry, and compare the spectrum with the Reference Spectrum or the spectrum of Roxithromycin Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

Optical rotation $[\alpha]_D^{20}$: -93 - $-96°$ (0.5 g calculated on the anhydrous basis, acetone, 50 mL, 100 mm).

Purity **(1)** Heavy metals—Proceed with 2.0 g of Roxithromycin according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 0.040 g of Roxithromycin in the mobile phase A to make 10 mL, and use this solution as the sample solution. Separately, dissolve 0.020 g of Roxithromycin Reference Standard in the mobile phase A to make exactly 10 mL. Pipet 1 mL of this solution, add the mobile phase A to make exactly 100 mL, and use this solution as the standard solution. Perform the test with 20 μL each of the sample solution and the standard solution as directed under the Liquid Chromatography according to the following conditions, and determine the peak areas by the automatic integration method: the area of a peak having the relative retention time of about 1.05 to the retention time of roxithromycin from the sample solution is not larger than 2 times of the peak area of roxithromycin from the standard solution. The areas of other than the peak of roxithromycin and the peak having the relative retention time of about 1.05 to the retention time of roxithromycin are not larger than the peak area of roxithromycin from the standard solution, and the total area of the peaks other than roxithromycin from the sample solution is not larger than 6 times of the peak area of roxithromycin from the standard solution.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 205 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase A: To 200 mL of a solution of ammonium dihydrogenphosphate (17 in 100) add 510 mL of water, and

adjust to pH 5.3 with 2 mol/L sodium hydroxide TS. To this solution add 315 mL of acetonitrile.

Mobile phase B: A mixture of acetonitrole and water (7:3).

Flowing of the mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (%)	Mobile phase B (%)
0 - 38	100	0
38 - 39	100→90	0→10
39 - 80	90	10

Flow rate: Adjust the flow rate so that the retention time of roxithromycin is about 21 minutes.

System suitability—

Test for required detection: To exactly 2 mL of the standard solution add the mobile phase A to make exactly 10 mL. Confirm that the peak area of roxithromycin obtained from 20 μL of this solution is equivalent to 15 to 25% of that of roxithromycin obtained from 20 μL of the standard solution.

System performance: Dissolve 5 mg each of Roxithromycin Reference Standard and *N*-demethylroxithromycin in the mobile phase A to make 100 mL. When the procedure is run with 20 μL of this solution under the above operating conditions, *N*-demethylroxithromycin and roxithromycin are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 5 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak areas of roxithromycin is not more than 2.0%.

Water Not more than 3.0% (0.3 g, volumetric titration, direct titration).

Residue on ignition Not more than 0.1% (1 g).

Assay Weigh accurately an amount of Roxithromycin and Roxithromycin Reference Standard, equivalent to about 0.02 g (potency), and dissolve separately in the mobile phase to make exactly 10 mL, and use these solutions as the sample solution and the standard solution. Perform the test with exactly 20 μL each of the sample solution and the standard solution as directed under the Liquid Chromatography according to the following conditions, and calculate the peak areas, A_T and A_S, of roxithromycin.

Amount [μg (potency)] of $C_{41}H_{76}N_2O_{15}$
= amount [mg (potency)] of Roxithromycin Reference Standard $\times \frac{A_T}{A_S} \times 1000$

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 205 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: To 200 mL of a solution of ammonium dihydrogenphosphate (17 in 100) add 510 mL of water, and adjust to pH 5.3 with 2 mol/L sodium hydroxide TS. To this solution add 315 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of roxithromycin is about 11 minutes.

System suitability—

System performance: Dissolve 5 mg each of Roxithromycin Reference Standard and *N*-demethylroxithromycin in the mobile phase to make 100 mL. When the procedure is run with 20 μL of this solution under the above operating conditions, *N*-demethylroxithromycin and roxithromycin are eluted in this order with the resolution between these peaks being not less than 6 and the symmetry coefficient of the peak of roxithromycin is not more than 1.5.

System repeatability: When, the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak areas of roxithromycin is not more than 1.0%.

Containers and storage Containers—Tight containers.

Salazosulfapyridine

Sulfasalazine

サラゾスルファピリジン



$C_{18}H_{14}N_4O_5S$: 398.39

2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)phenylazo]benzoic acid [*599-79-1*]

Salazosulfapyridine, when dried, contains not less than 96.0% of $C_{18}H_{14}N_4O_5S$.

Description Salazosulfapyridine occurs as a yellow to yellow-brown, fine powder. It is odorless and tasteless.

It is sparingly soluble in pyridine, slightly soluble in ethanol (95), practically insoluble in water, in chloroform and in diethyl ether.

It dissolves in sodium hydroxide TS.

Melting point: 240 - 249°C (with decomposition).

Identification (1) Dissolve 0.1 g of Salazosulfapyridine in 20 mL of dilute sodium hydroxide TS: a red-brown color develops. This color gradually fades upon gradual addition of 0.5 g of sodium hydrosulfite with shaking. Use this solution in the following tests (2) to (4).

(2) To 1 mL of the solution obtained in (1) add 40 mL of water, neutralize with 0.1 mol/L hydrochloric acid TS, and add water to make 50 mL. To 5 mL of this solution add 2 to 3 drops of dilute iron (III) chloride TS: a red color develops and changes to purple, then fades when dilute hydrochloric acid is added dropwise.

(3) The solution obtained in (1) responds to the Qualitative Tests for primary aromatic amines.

(4) To 1 mL of the solution obtained in (1) add 1 mL of